EXEL Stock Analysis — Exelixis
Sector: Healthcare
AI Verdict
EXEL trades at 13.3x next year's earnings with 15.3% EPS growth expected—cheap for the growth on offer if its oncology pipeline continues to deliver.
Competitive Moat
Exelixis specializes in oncology therapeutics, with a defensible position built on its proprietary small-molecule drug pipeline and established partnerships with larger pharma companies. Its lead drug, cabozantinib, has multiple approved indications, creating a recurring revenue base and clinical data moat.
Summary
Exelixis trades at a discount to the healthcare sector on forward earnings, with double-digit EPS growth expected.
Where It Stands
EXEL delivered 6.8% revenue growth last year, trades at 13.3x forward earnings versus the healthcare median of 22x, and its trailing P/E is 15.3x.
Key Metrics
- Trailing P/E: 15.3x
- Forward P/E: 13.3x
- PEG Ratio: 1.00
- Earnings Growth: +0.2%
- Revenue Growth: +0.1%
- 52-Week High: $49.62
- 52-Week Low: $33.76
Analyst Consensus
15 Buy · 10 Hold · 1 Sell (26 analysts)
Bull Case
Analysts expect 15.3% EPS growth next year, making the 13.3x forward P/E look cheap relative to sector norms.
Bear Case
If EXEL's P/E rerates up to the sector median of 22x, shares could look expensive if future growth disappoints or clinical setbacks occur.
Catalyst to Watch
Watch for clinical trial readouts or regulatory decisions on pipeline drugs, as positive results could justify the current multiple.